Percutaneous coronary interventions in octogenarians glycoprotein IIb/IIIa receptor inhibitors’ safety profile by Sadeghi, H.Mehrdad et al.
Interventional Cardiology
Percutaneous Coronary Interventions
in Octogenarians: Glycoprotein
IIb/IIIa Receptor Inhibitors’ Safety Profile
H. Mehrdad Sadeghi, MD, Cindy L. Grines, MD, FACC, Harish R. Chandra, MD, MPH,
Simon R. Dixon, MBCHB, FRACP, Judith A. Boura, MS, Srinivas Dukkipati, MD, Kishore J. Harjai, MD,
William W. O’Neill, MD, FACC
Royal Oak, Michigan
OBJECTIVES This study was designed to evaluate the safety profile of glycoprotein IIb/IIIa receptor
inhibitors (GPI) in octogenarians undergoing percutaneous coronary intervention (PCI).
BACKGROUND Patients80 years old constitute the fastest growing segment of the U.S. population and have
a high prevalence of coronary artery disease. Few data exist regarding the use of GPI during
PCI in octogenarians, as these patients have been excluded from randomized clinical trials of
GPI.
METHODS Consecutive patients 80 years old undergoing PCI between January 1998 and June 2001
were evaluated for clinical outcomes and bleeding complications.
RESULTS One thousand three hundred and ninety two of 14,308 patients (9.7%) undergoing PCI were
80 years old. Of these, 459 of 1,392 (33%) of the patients were treated with GPI.
Octogenarians treated with GPI were more likely to present with acute coronary syndrome or
infarction, receive stents, require an intra-aortic balloon pump, or undergo multi-vessel PCI.
Glycoprotein receptor inhibitor use was associated with a higher rate of bleeding, but the
transfusion rate was similar to that in patients who did not receive GPI (9.8% vs. 8.6%, p 
NS). No cases of intracranial hemorrhage were observed. By multivariate analysis, GPI
treatment was associated with longer hospitalization but did not independently predict the
need for transfusion or affect mortality.
CONCLUSIONS Octogenarians have a high incidence of bleeding and need for transfusion after PCI.
Although the use of GPI was associated with more access and non-access site bleeding and
longer hospital stay, GPI treatment does not significantly increase the risk of transfusion or
intracranial hemorrhage in this non-randomized cohort. (J Am Coll Cardiol 2003;42:
428–32) © 2003 by the American College of Cardiology Foundation
Patients older than 80 years of age constitute the fastest
growing segment of the U.S. population and have a high
prevalence of coronary artery disease (1,2). In the era of the
dramatic growth of percutaneous coronary intervention
(PCI), octogenarians’ cardiac and non-cardiac comorbidities
are likely to be associated with higher complication rates
during PCI (3–7). Although glycoprotein IIb/IIIa receptor
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inhibitors (GPI) are increasingly used in accordance to
American College of Cardiology/American Heart Associa-
tion guidelines (8) to reduce the incidence of ischemic
complications in patients presenting with acute coronary
syndrome (ACS) and also during PCI, few efficacy and
safety data exist regarding the use of GPI in octogenarian
patients. Randomized clinical trials have routinely enrolled
patients younger than 75 to 80 years old. Limited data on
elderly patients (generally younger than 80 years) showed
that the relative benefits of GPI in older patients are similar
to those of younger patients, but this may even translate into
a greater absolute benefit in light of higher event rates
(9–11). Nonetheless, a major concern with octogenarians
and nonagenarians is the risk of bleeding—especially of
intracranial hemorrhage. The purpose of this study was to
assess the safety profile of GPI treatment in octogenarians
undergoing PCI.
METHODS
Study population. All patients 80 years old undergoing
elective or emergency PCI at William Beaumont Hospital
between January 1998 and June 2001 were included in the
study. Patients were stratified according to GPI treatment.
Percutaneous intervention. Balloon angioplasty, atherec-
tomy (rotational or extraction), or stent implantation, either
alone or in combination were performed at the operators’
discretion. The activated clotting time was maintained at
250 to 300 s during the procedure, depending on whether
or not a GPI was used. Early sheath removal and avoidance
of post-intervention heparin were encouraged. All patients
From the Division of Cardiology, William Beaumont Hospital, Royal Oak,
Michigan. Presented in part at the 51st Annual Scientific Session of the American
College of Cardiology, Atlanta, Georgia, March 2002.
Manuscript received November 18, 2002; revised manuscript received January 29,
2003, accepted February 20, 2003.
Journal of the American College of Cardiology Vol. 42, No. 3, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00657-0
were taking aspirin, and patients received either ticlodipine
or clopidogrel for two to four weeks if they received a stent.
Individual operators dictated other medications.
Data collection and definitions. Baseline clinical and
catheterization data were obtained prospectively at the time
of the procedure by research nurses and entered into a
computerized database. Clinical outcomes and any adverse
events were reported by operators and confirmed by dedi-
cated research nurses. At least one creatine kinase-MB
fraction (CK-MB) assay was obtained 8 to 12 h after PCI.
Non–Q-wave myocardial infarction (MI) was defined as a
single CK-MB 3 upper limit of normal (or 50% rise if
abnormal baseline value) in the absence of pathologic Q
waves. Serum creatinine was routinely measured at 24 h,
with additional measurements in patients with baseline
renal insufficiency or those hospitalized longer. Acute renal
failure was defined as 1.0 mg/dl serum creatinine rise from
baseline levels. Creatinine clearance was calculated using the
Cockcroft-Gault formula (12). Access site bleeding was
defined as a hematoma 3 cm.
Statistical analysis. Data analysis was performed using
SAS software (version 8.0, SAS Inc., Cary, North Caroli-
na). Results are expressed as percentages, mean  SD, or
median (25th, 75th percentile). The Fisher exact or chi-
square test (when expected frequency 5) was used to
compare categorical variables. Continuous variables were
compared using the Student two-sided t test, but creatinine,
creatinine clearance, contrast amount, and length of stay
(LOS) were compared using the Wilcoxon rank test because
of their non-normal distribution. Independent predictors of
LOS and transfusion requirement were determined by step
down multivariate analysis of variance model and logistic
regression analysis, respectively. A p value 0.05 was
considered statistically significant.
RESULTS
Baseline characteristics. Between January 1998 and June
2001, 14,308 patients underwent PCI at William Beaumont
Hospital. One thousand three hundred and ninety two
(9.7%) patients were80 years of age (range 80 to 98 years;
25% 85 years). Of these, 459 (33%) received a GPI at the
operators’ discretion. Baseline characteristics for octogenar-
ians are shown in Table 1. Most received eptifibatide (73%),
which was infused for 12 to 18 h. Abciximab (27%) was
infused for 12 h. Glycoprotein inhibitor treatment was
stopped early if bleeding occurred. Patients treated with
GPI were more likely to be male and to present with an
ACS or acute MI and were less likely to have peripheral
vascular disease (19% vs. 25%, p  0.05) or peptic ulcer
disease (14% vs. 18%, p  0.049).
Procedural data. Patients treated with GPI were more
likely to be treated with a stent (77% vs. 69%, p 0.05) and
undergo multi-vessel PCI (23% vs. 17%, p  0.05) (Table
2). Patients treated with GPI received a larger volume of
contrast, consistent with the greater use of multi-vessel PCI
in this group. The use of venous sheaths was similar
between the two groups. Intra-aortic balloon pumps
Table 2. Procedural Data in Octogenarians Undergoing PCI
Variables
No GPI
(n  933)
GPI
(n  459)
Glycoprotein receptor inhibitor
Abciximab (%) — 27
Eptifibatide (%) — 73
Number of vessels treated† 1 (1, 1) 1 (1, 1)
One vessel (%) 83 77*
Two vessels (%) 16 20*
3 vessels (%) 1 3*
Patients with venous sheaths (%) 32 31
Venous sheath size (F)† 6.0 (6.0, 7.0) 7.0 (6.0, 7.0)
Arterial sheath size (F)† 7.0 (6.0, 8.0) 7.0 (6.0, 7.0)
Intra-aortic balloon pump (%) 1.7 5.5*
Stents (%) 69 77*
Debulking devices (%) 5 9*
Total contrast amount (cc) 197  83 215  84*
Peak activated clotting time (s) 344  79 336  73
Heparin dose (U) 7,687  3,998 5,693  4,494*
Heparin infusion post-PCI (%) 7 8
*p  0.05. †Values in parentheses represent 25th and 75th percentiles.
Abbreviations as in Table 1.
Abbreviations and Acronyms
ACS  acute coronary syndrome
CK-MB  creatine kinase-MB fraction
GPI  glycoprotein IIb/IIIa receptor inhibitor
IABP  intra-aortic balloon pump
LOS  length of stay after PCI
MI  myocardial infarction
PCI  percutaneous coronary intervention
Table 1. Baseline Demographic, Clinical, and Laboratory
Characteristics of Octogenarians Undergoing PCI With or
Without a Glycoprotein Receptor Inhibitor
Variables
No GPI
(n  933)
GPI
(n  459)
Age (yrs) 83  3 83  3
Female (%) 52 43*
Weight (kg) 72  15 74  15
Hypertension (%) 75 71
Diabetes (%) 27 25
Hypercholesterolemia (%) 55 59
Current smoker (%) 3.4 5.2
Congestive heart failure (%) 28 27
Myocardial infarct 2 weeks (%) 16 25*
Prior coronary artery bypass surgery (%) 27 25
Prior stroke (%) 16 13
Prior peptic ulcer disease (%) 18 14*
Prior peripheral vascular disease (%) 25 19*
Baseline hematocrit (%) 37  5 38  5*
Baseline creatinine clearance (cc/min) 49  21 47  19
PCI indication
Elective (%) 92 83*
Acute coronary syndrome or infarct (%) 8 17*
*p  0.05.
GPI  glycoprotein IIb/IIIa receptor inhibitors; PCI  percutaneous coronary
intervention.
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(IABPs) were required more frequently in patients treated
with GPI (5.5% vs. 1.7%, p  0.01). The peak cath-lab
activated clotting time was slightly lower (p  0.054) in the
GPI group. All patients received a thienopyridine after
stenting.
Bleeding complications. Table 3 shows the incidence of
bleeding complications. Glycoprotein inhibitor use was
associated with a higher incidence of access site and non-
access site bleeding. There was no difference in the inci-
dence of retroperitoneal hemorrhage between groups, but
gastro-intestinal bleeding was more frequent after GPI use.
Upper airway bleeding was almost always related to trauma
from endotracheal intubation or other instrumentation.
There were no cases of pulmonary or intracranial hemor-
rhage in either group. Overall, the rate of transfusion was
similar in both groups. Transfusion requirements and the
number of red-cell units given to each patient (range 1 to 11
U) were similar. The proportion of patients in each group
who required3 U of red-cell transfusion was similar (1.0%
to 1.5%).
Clinical outcomes. Patients with ST-segment elevation
infarctions or no post-intervention CK-MB value were
excluded from non–Q-wave MI analysis (11%). After PCI,
non–Q-wave MI was more prevalent in the GPI group,
whereas in-hospital mortality rates were similar between the
two groups (Table 4). Length of stay was longer in the GPI
group (p  0.05). Median and 90th percentile LOS were
one day longer for the GPI group.
Multivariate analysis. GPI treatment was not a significant
predictor of transfusion requirement but was associated with
longer LOS. Transfusion requirement was best predicted by
non-access site bleeds and IABP requirement (odds ratio
[OR]  11.1 [4.7 to 26.1] and OR  15.4 [6.7 to 35.1,
respectively, p  0.0001]). Length of stay was best pre-
dicted by male gender, creatinine clearance, peak creatinine,
recent infarction, new stroke, and transfusion (p  0.0001)
as well as GPI use (p  0.01).
DISCUSSION
Octogenarians represent an increasing proportion of pa-
tients presenting to cardiac catheterization laboratories
around the country (2,13). Previous studies have reported a
higher rate of ischemic complications after PCI in older
patients (6). This is presumably a manifestation of associ-
ated comorbidities (14), including peripheral vascular dis-
ease, renal insufficiency, and anemia. In this study, 23%,
16%, and 6% of patients had peripheral vascular disease,
severe renal insufficiency (creatinine clearance 30 cc/min),
and severe anemia (hematocrit 30%), respectively. In
addition to the higher prevalence of comorbidities in the
elderly, arteries are prone to age-related changes such as
medial calcification, more extensive atherosclerosis, dilation,
tortuosity, and impairment of endothelial function. These
factors contribute to a decline in procedural success and
higher ischemic and bleeding complications with PCI in the
elderly.
Glycoprotein inhibitor treatment plays a key role in the
contemporary management of patients undergoing PCI.
Several large-scale randomized clinical trials have noted
GPI’s ability to reduce ischemic complications (namely,
peri-procedural cardiac enzyme elevations) (9,15–19). On
the basis of these data, GPI are now widely used to
minimize ischemic complications during PCI. Glycoprotein
inhibitor use has extended to octogenarians despite their
exclusion from most randomized clinical trials (20).
This study evaluated the safety profile of GPI treatment
(73% eptifibatide) in an unselected cohort of octogenarians
undergoing elective and emergency PCI. Octogenarians
treated with GPI had a higher incidence of bleeding and
longer hospital stay. Access site bleeds were increased in the
GPI group, which is consistent with observations from
randomized clinical trials (9,11,17). Severe vascular access
bleeding associated with a 10% hematocrit decline was
nearly twice as likely with GPI treatment. Non-access site
bleeds, mainly gastrointestinal bleeds, were also more fre-
quent with GPI use. However, there was no increase in the
risk of intracranial, pulmonary, or retroperitoneal hemor-
Table 3. Bleeding Complications in Octogenarians Undergoing
PCI With or Without a Glycoprotein Receptor Inhibitor
Variables
No GPI
(n  933)
GPI
(n  459)
Access site
Vascular access bleed (%) 20 26*
Bleed with decrease in hematocrit 10% (%) 4.2 7.8*
Non-access site bleed (%) 2.6 5.2*
Intracranial hemorrhage (%) 0 0
Retroperitoneal hemorrhage (%) 0.5 0.4
Pulmonary hemorrhage (%) 0 0
Gastrointestinal bleed (%) 0.8 2.2*
Genito-urinary bleed (%)† 0.8 1.5
Upper airway bleed (%) 0.4 0.9
Red-cell transfusion (%) 8.6 9.8
Transfusion (red-cell U/bleed) 2.2 2.3
*p  0.05. †Macroscopic hematuria.
Abbreviations as in Table 1.
Table 4. In-Hospital Outcomes in Octogenarians Undergoing
PCI With or Without a Glycoprotein Receptor Inhibitor
Outcome
No GPI
(n  933)
GPI
(n  459)
Death 3.0 3.1
New Q-wave myocardial infarct (%) 0.2 0.7
Non–Q-wave myocardial infarct (%)† 2.7 5.9*
Urgent revascularization (%) 1.0 1.5
Non-hemorrhagic stroke (%) 0.8 0
Surgical vascular repair (%) 0.3 0
Acute renal failure or need for dialysis (%) 2.6 2.8
Length of stay after intervention (days)
(mean  SD) 3.1  5 3.6  4*
(median [90th %]) 1 [7] 2 [8]*
*p  0.05. †Excludes patients with ST-segment elevation infarcts or no post-
intervention creatine kinase-MB value.
Abbreviations as in Table 1.
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rhage. The overall rate of transfusion was similar in both
patient groups. Furthermore, patients treated with GPI had
higher rates of stenting, which can potentially confound
comparison of ischemic events and bleeding complications
between the two groups. Higher rate of thienopyridine use
can increase the risk of bleeding and the need for transfusion
(21,22). By multivariate analysis, non-access site bleeding
and IABP use, but not GPI treatment, were independently
associated with a requirement for transfusion.
In the Evaluation of Platelet IIb/IIIa Inhibitor for Stent-
ing (EPISTENT) trial, the use of abciximab was associ-
ated with major and minor bleeding rates of 1.5% and
2.9%, respectively (17). In the Enhanced Suppression of
the Platelet IIb/IIIa Receptor with Integrilin Therapy
(ESPRIT) trial, major, minor bleeding, and transfusion
rates were seen in 1.0%, 2.8%, and 1.0% of patients treated
with eptifibatide, respectively (9). In our study, the inci-
dence of bleeding complications in octogenarians was
higher than the rates from randomized trials. However, the
GPI trials represent a select population and did not enroll
octogenarians. In our experience, transfusion requirements
with GPI treatment for patients 75 years old are compa-
rable to the results of recent randomized trials.
In our study, there was a higher incidence of post-
procedural MI in the GPI group. However, patients treated
with GPI were more likely to have presented with an ACS
and have multi-vessel PCI performed, thus suggesting that
operators selected ‘higher-risk’ patients for adjunctive GPI
therapy. The in-hospital mortality in this cohort was 3%,
which is higher than in recent reports (5). This reflects the
higher-risk profile of octogenarian patients being referred
for PCI in the present era. In this non-randomized com-
parison, no difference in in-hospital mortality or other
clinical outcomes was observed in either patient group.
Length of stay after PCI can be used as a surrogate
marker for procedural complications and adverse events. For
instance, LOS has been demonstrated to increase with
bleeding complications in previous GPI trials, with an
increase in median LOS from one to four days with minor
and major bleeds, respectively (23,24). The median LOS
was one day longer for the GPI group and was best
predicted by male gender, creatinine clearance, recent MI,
new stroke, and transfusion requirement by multivariate
analysis. Longer LOS was also independently associated
with GPI use (p  0.01).
Study limitations. Our study represents an observational
study where patient data were retrieved from the William
Beaumont Hospital database after it had been obtained and
recorded prospectively. It has limitations that are associated
with a single-center, non-randomized study, but it repre-
sents a large “real-life” experience of PCI in octogenarians.
Selection criteria for GPI treatment were not prospectively
defined, limiting the application of our findings. Clinical
outcomes and adverse events were either reported by oper-
ators or recorded from chart review by dedicated research
nurses without an adjudication process. Bleeding complica-
tions were not reported according to Thrombolysis In
Myocardial Infarction criteria (25), which makes it more
difficult to compare our cohort’s bleeding complications
with previously reported randomized trials’ results. Further-
more, few data exist regarding the appropriate indications
for blood transfusion in patients with coronary artery disease
(26,27); as a result, transfusion requirement is at the
discretion of clinicians.
Conclusions. Octogenarians have a relatively high risk of
procedural mortality and bleeding complications related to
their increased comorbidities, which include a higher inci-
dence of cardiovascular disease, atherosclerosis burden, pe-
ripheral vascular disease, renal insufficiency, and anemia.
Although octogenarians have greater bleeding and longer
hospitalizations after GPI treatment, GPI therapy did not
portend any additional and independent risk of transfusion
after PCI and may be used cautiously in selected octoge-
narians. Percutaneous coronary intervention is associated
with a higher risk of acute morbidity in octogenarians
despite improved outcomes using modern interventional
techniques, and it should be considered in the context of a
critical and conservative assessment. Randomized trials
would be required to definitively establish and confirm the
efficacy and safety of GPI treatment in this population.
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